Business Description
Arovella Therapeutics Ltd
ISIN : AU0000182784
Compare
Compare
Traded in other countries / regions
ALA.AustraliaE4NA.Germany IPO Date
2002-01-24Description
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.59 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 24.68 | |||||
Beneish M-Score | -6.58 | |||||
WACC vs ROIC |
Growth Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -30.7 | |||||
3-Year EBITDA Growth Rate | 39.9 | |||||
3-Year EPS without NRI Growth Rate | 22.7 | |||||
3-Year FCF Growth Rate | 22 | |||||
3-Year Book Growth Rate | -45.7 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 82.36 | |||||
9-Day RSI | 75.28 | |||||
14-Day RSI | 69.24 | |||||
6-1 Month Momentum % | -4.17 | |||||
12-1 Month Momentum % | 130 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.37 | |||||
Quick Ratio | 2.37 | |||||
Cash Ratio | 2.18 | |||||
Days Sales Outstanding | 483.19 | |||||
Days Payable | 21413.33 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -71.7 | |||||
Shareholder Yield % | -5.21 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 34.29 | |||||
Operating Margin % | -30608.57 | |||||
Net Margin % | -29222.86 | |||||
FCF Margin % | -18414.29 | |||||
ROE % | -274.68 | |||||
ROA % | -184.18 | |||||
ROIC % | -1073.81 | |||||
ROC (Joel Greenblatt) % | -7309.29 | |||||
ROCE % | -274.12 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 155 | |||||
PB Ratio | 51.67 | |||||
EV-to-EBIT | -15.57 | |||||
EV-to-Forward-EBIT | -9.51 | |||||
EV-to-EBITDA | -15.78 | |||||
EV-to-Forward-EBITDA | -8.66 | |||||
EV-to-Revenue | 4553.2 | |||||
EV-to-Forward-Revenue | 4.8 | |||||
EV-to-FCF | -22.28 | |||||
Price-to-Median-PS-Value | 15.5 | |||||
Earnings Yield (Greenblatt) % | -6.43 | |||||
FCF Yield % | -3.96 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Arovella Therapeutics Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil A$) | 0.035 | ||
EPS (TTM) (A$) | -0.013 | ||
Beta | 0.3 | ||
Volatility % | 69.13 | ||
14-Day RSI | 69.24 | ||
14-Day ATR (A$) | 0.009875 | ||
20-Day SMA (A$) | 0.1375 | ||
12-1 Month Momentum % | 130 | ||
52-Week Range (A$) | 0.042 - 0.185 | ||
Shares Outstanding (Mil) | 1,050.56 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Arovella Therapeutics Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Arovella Therapeutics Ltd Stock Events
Event | Date | Price(A$) | ||
---|---|---|---|---|
No Event Data |
Arovella Therapeutics Ltd Frequently Asked Questions
What is Arovella Therapeutics Ltd(ASX:ALA)'s stock price today?
The current price of ASX:ALA is A$0.16. The 52 week high of ASX:ALA is A$0.19 and 52 week low is A$0.04.
When is next earnings date of Arovella Therapeutics Ltd(ASX:ALA)?
The next earnings date of Arovella Therapeutics Ltd(ASX:ALA) is 2025-02-28 Est..
Does Arovella Therapeutics Ltd(ASX:ALA) pay dividends? If so, how much?
Arovella Therapeutics Ltd(ASX:ALA) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |